---
title: "IBRX"
subtitle: "Stock Analysis by ChatGPT"
date: 2023-12-18T00:56:00
draft: true
tags: ['Immunotherapy', 'Clinical-stage development', 'FDA review', 'Biologics License Application', 'Financial transactions']
author: Friday Wall
---

score:126
### Chances:
1. ImmunityBio, Inc. is making significant progress in its clinical-stage immunotherapy development, as evidenced by its participation in the 35th Annual Piper Sandler Healthcare Conference and the acceptance for review of its Biologics License Application by the FDA.
2. The company's Memory Cytokine-Enriched Natural Killer cells (M-ceNK) have shown promising results in the treatment of small cell lung cancer and neuroendocrine tumors, indicating a potential breakthrough in immunotherapy.
### Risks:
1. Despite the positive developments, there is still a risk associated with the outcome of the FDA review process for N-803 and its potential approval for the treatment of non-muscle-invasive bladder cancer carcinoma in situ (CIS).
2. The company's financial transactions and insider control raise concerns about potential conflicts of interest and governance issues.
### Score:126
chances characters count - risks characters count = -874

investment score = 1000 + chances characters count - risks characters count
{{<tradingview symbol="Nasdaq:IBRX">}}
### References:
- 2023-11-16 [ImmunityBio to Participate in 35th Annual Piper Sandler Healthcare Conference](https://finance.yahoo.com/news/immunitybio-participate-35th-annual-piper-140000137.html)
- 2023-11-07 [First Data for ImmunityBio’s Memory Cytokine-Enriched NK Cells in Small Cell Lung Cancer at SITC Meeting Show Promising Anti-tumor Activity](https://finance.yahoo.com/news/first-data-immunitybio-memory-cytokine-140000492.html)
- 2023-10-26 [FDA Accepts ImmunityBio’s BLA Resubmission as Complete and Sets New PDUFA Date](https://finance.yahoo.com/news/fda-accepts-immunitybio-bla-resubmission-130000546.html)
- 2023-10-23 [ImmunityBio Announces Biological License Application Resubmission for N-803 in BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer Carcinoma-In-Situ](https://finance.yahoo.com/news/immunitybio-announces-biological-license-application-130000888.html)
- 2023-09-11 [ImmunityBio Announces $470 Million Equity and Debt Financing From Founder, Dr. Patrick Soon-Shiong and Nant Entities](https://finance.yahoo.com/news/immunitybio-announces-470-million-equity-100000603.html)
- 2023-09-08 [ImmunityBio, Inc. (NASDAQ:IBRX) Top Key Executive Patrick Soon-Shiong's holdings dropped 14% in value as a result of the recent pullback](https://finance.yahoo.com/news/immunitybio-inc-nasdaq-ibrx-top-145550154.html)
- 2023-08-03 [ImmunityBio Names Enrique Diloné as Chief Technology Officer](https://finance.yahoo.com/news/immunitybio-names-enrique-dilon-chief-130000568.html)
- 2023-07-21 [ImmunityBio Announces Execution of $40 Million Equity Financing with Institutional Investors](https://finance.yahoo.com/news/immunitybio-announces-execution-40-million-003200481.html)
- 2023-07-10 [Phase 1 Study Indicates Allogeneic Cytokine-Induced Memory-Like Natural Killer Cells Plus N-803 May Induce Tumor Regression in Advanced Head-and-Neck Cancer Patients](https://finance.yahoo.com/news/phase-1-study-indicates-allogeneic-133000260.html)
- 2023-05-22 [ImmunityBio to Participate in the Jefferies Global Healthcare Conference](https://finance.yahoo.com/news/immunitybio-participate-jefferies-global-healthcare-130000958.html)


                